Evidence map›Paper›PMID 19525947›Full record

ReviewNature materials2009

Understanding biophysicochemical interactions at the nano-bio interface.

Andre E Nel, Lutz Mädler, Darrell Velegol, Tian Xia, Eric M V Hoek, Ponisseril Somasundaran, Fred Klaessig, Vince Castranova, Mike Thompson

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature materials, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02465593 (A Phase Ib/II Study of PEP503), which is not on this map. Cited by 1,750 papers.

0numbers the graph read from it
0cells of the map it votes in
1,750citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02465593 phase1 / phase2terminatednot on this mapstarted 2015, after this paper: background citation

A Phase Ib/II Study of PEP503 (Radioenhancer) With Radiotherapy, in Combination With Concurrent Chemotherapy for Patients With Locally Advanced or Unresectable Rectal Cancer

TypeinterventionalSponsorPharmaEngineRan2015 to 2021Enrolled32ConditionsRectal CancerArmsPEP503, 5-fluorouracil, capecitabine, surgical resection, Radiotherapy
3 · Its place in the literature

Who cites it

1,750 citing papers in PubMed.

  1. Trial
  2. A photothermal ablation strategy for orthotopic ovarian cancerInternational journal of pharmaceutics: X · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

1,690 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andre E NelDivision of NanoMedicine, David Geffen School of Medicine and California NanoSystems Institute at UCLA, Los Angeles, California 90095, USA. anel@mednet.ucla.edu
Lutz Mädler
Darrell Velegol
Tian Xia
Eric M V Hoek
Ponisseril Somasundaran
Fred Klaessig
Vince Castranova
Mike Thompson

Funding

Xenobiotics, Oxidative Stress and Allergic InflammationU19AI070453 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS · 2006 to 2010
$6.7M
Predictive Toxicological Paradigm for Chronic Nanoparticle Injury in the LungR01ES016746 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS · 2008 to 2017
$3.4M
Development of methods and models for nanoparticle toxicity screening: ApplicatioR01ES015498 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS · 2006 to 2008
$384k
NIAID NIH HHS U19 AI070453NIEHS NIH HHS R01 ES015498NIEHS NIH HHS R01 ES016746
6 · The paper itself

Abstract

Rapid growth in nanotechnology is increasing the likelihood of engineered nanomaterials coming into contact with humans and the environment. Nanoparticles interacting with proteins, membranes, cells, DNA and organelles establish a series of nanoparticle/biological interfaces that depend on colloidal forces as well as dynamic biophysicochemical interactions. These interactions lead to the formation of protein coronas, particle wrapping, intracellular uptake and biocatalytic processes that could have biocompatible or bioadverse outcomes. For their part, the biomolecules may induce phase transformations, free energy releases, restructuring and dissolution at the nanomaterial surface. Probing these various interfaces allows the development of predictive relationships between structure and activity that are determined by nanomaterial properties such as size, shape, surface chemistry, roughness and surface coatings. This knowledge is important from the perspective of safe use of nanomaterials.

Indexed as

Biocompatible MaterialsModels, BiologicalNanoparticlesNanotechnologyParticle SizeProteinsBiocompatible MaterialsProteins

Identifiers

PMID19525947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.